epirubicin has been researched along with Thyroid Cancer, Anaplastic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Deng, W; Guo, P; Guo, W; Hao, J; Hu, S; Hua, Y; Li, W; Li, Y; Liao, Y; Long, Q; Sui, S; Sun, Y; Tian, C; Wang, R; Wang, X; Xie, F; Yu, W; Zhang, C; Zou, K; Zou, L; Zuo, Y | 1 |
| Cartei, F; Cocuzza, P; Colosimo, C; Fiorica, F; Greco, C; Mazzotti, V; Pedriali, M; Stefanelli, A; Taibi, R; Ursino, S | 1 |
1 review(s) available for epirubicin and Thyroid Cancer, Anaplastic
| Article | Year |
|---|---|
Anaplastic thyroid cancer: a case report of a long term survival patient and review of literature data.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Humans; Male; Middle Aged; Neoplasm Invasiveness; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Thyroidectomy; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
1 other study(ies) available for epirubicin and Thyroid Cancer, Anaplastic
| Article | Year |
|---|---|
CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Epirubicin; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Male; Mediator Complex; Mice; Mice, Inbred BALB C; Mice, Nude; Signal Transduction; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2021 |